KR20170024165A - 결정 - Google Patents

결정 Download PDF

Info

Publication number
KR20170024165A
KR20170024165A KR1020177005424A KR20177005424A KR20170024165A KR 20170024165 A KR20170024165 A KR 20170024165A KR 1020177005424 A KR1020177005424 A KR 1020177005424A KR 20177005424 A KR20177005424 A KR 20177005424A KR 20170024165 A KR20170024165 A KR 20170024165A
Authority
KR
South Korea
Prior art keywords
present
powder
crystal
crystals
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177005424A
Other languages
English (en)
Korean (ko)
Inventor
히데유키 이토우
고지 나카미치
다카시 도사카
Original Assignee
니뽄 신야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43386634&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170024165(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 니뽄 신야쿠 가부시키가이샤 filed Critical 니뽄 신야쿠 가부시키가이샤
Publication of KR20170024165A publication Critical patent/KR20170024165A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
KR1020177005424A 2009-06-26 2010-06-25 결정 Ceased KR20170024165A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2009151729 2009-06-26
JP2009151727 2009-06-26
JPJP-P-2009-151727 2009-06-26
JPJP-P-2009-151729 2009-06-26
JPJP-P-2009-151728 2009-06-26
JP2009151728 2009-06-26
PCT/JP2010/060798 WO2010150865A1 (ja) 2009-06-26 2010-06-25 結晶

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127000526A Division KR102669213B1 (ko) 2009-06-26 2010-06-25 결정

Publications (1)

Publication Number Publication Date
KR20170024165A true KR20170024165A (ko) 2017-03-06

Family

ID=43386634

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020177005424A Ceased KR20170024165A (ko) 2009-06-26 2010-06-25 결정
KR1020247016901A Active KR102705198B1 (ko) 2009-06-26 2010-06-25 결정
KR1020127000526A Active KR102669213B1 (ko) 2009-06-26 2010-06-25 결정
KR1020257021877A Pending KR20250107951A (ko) 2009-06-26 2010-06-25 결정
KR1020247016902A Active KR102829415B1 (ko) 2009-06-26 2010-06-25 결정

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020247016901A Active KR102705198B1 (ko) 2009-06-26 2010-06-25 결정
KR1020127000526A Active KR102669213B1 (ko) 2009-06-26 2010-06-25 결정
KR1020257021877A Pending KR20250107951A (ko) 2009-06-26 2010-06-25 결정
KR1020247016902A Active KR102829415B1 (ko) 2009-06-26 2010-06-25 결정

Country Status (33)

Country Link
US (4) US8791122B2 (cg-RX-API-DMAC10.html)
EP (3) EP2447254B1 (cg-RX-API-DMAC10.html)
JP (1) JPWO2010150865A1 (cg-RX-API-DMAC10.html)
KR (5) KR20170024165A (cg-RX-API-DMAC10.html)
CN (2) CN102459198B (cg-RX-API-DMAC10.html)
AR (1) AR077242A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010263569B2 (cg-RX-API-DMAC10.html)
BR (2) BR122021005510B1 (cg-RX-API-DMAC10.html)
CA (1) CA2764475C (cg-RX-API-DMAC10.html)
CL (1) CL2011003264A1 (cg-RX-API-DMAC10.html)
CO (1) CO6430432A2 (cg-RX-API-DMAC10.html)
CY (3) CY1119788T1 (cg-RX-API-DMAC10.html)
DK (2) DK3275871T3 (cg-RX-API-DMAC10.html)
ES (2) ES2797124T3 (cg-RX-API-DMAC10.html)
HR (2) HRP20180171T1 (cg-RX-API-DMAC10.html)
HU (3) HUE048467T2 (cg-RX-API-DMAC10.html)
IL (3) IL216928A (cg-RX-API-DMAC10.html)
LT (3) LT3275871T (cg-RX-API-DMAC10.html)
MA (1) MA33637B1 (cg-RX-API-DMAC10.html)
MX (2) MX2011013471A (cg-RX-API-DMAC10.html)
MY (1) MY186531A (cg-RX-API-DMAC10.html)
NO (2) NO2447254T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ597352A (cg-RX-API-DMAC10.html)
PH (2) PH12015502825A1 (cg-RX-API-DMAC10.html)
PL (2) PL2447254T3 (cg-RX-API-DMAC10.html)
PT (2) PT3275871T (cg-RX-API-DMAC10.html)
RU (1) RU2556206C3 (cg-RX-API-DMAC10.html)
SG (2) SG176915A1 (cg-RX-API-DMAC10.html)
SI (2) SI3275871T1 (cg-RX-API-DMAC10.html)
SM (2) SMT201800077T1 (cg-RX-API-DMAC10.html)
TW (1) TWI531565B (cg-RX-API-DMAC10.html)
WO (1) WO2010150865A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201109099B (cg-RX-API-DMAC10.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246336B1 (en) * 2008-02-28 2020-07-01 Nippon Shinyaku Co., Ltd. Fibrosis inhibitor
US8575175B2 (en) * 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
CN106279047B (zh) * 2015-05-13 2019-05-03 普济生物科技(台州)有限公司 一种前列环素受体激动剂的制备方法
WO2016193994A1 (en) 2015-05-29 2016-12-08 Megafine Pharma (P) Ltd. Amorphous selexipag and process for preparation thereof
WO2017029594A1 (en) * 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Processes for preparation of selexipag and its amorphous form
ES2762943T3 (es) 2015-09-03 2020-05-26 Teva Pharmaceuticals Int Gmbh Formas de Selexipag en estado sólido
WO2017042731A1 (en) 2015-09-10 2017-03-16 Lupin Limited Amorphous form of selexipag and solid dispersion thereof
WO2017042828A2 (en) * 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Process for the preparation of selexipag and intermediates thereof
SG11201804320QA (en) 2015-12-02 2018-06-28 Nippon Shinyaku Co Ltd Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
WO2017109772A1 (en) * 2015-12-20 2017-06-29 Mapi Pharma Ltd. Amorphous form of selexipag
EP3192502A1 (en) 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag
US10815204B2 (en) 2016-04-01 2020-10-27 Honour (R&D) Process for the preparation of diphenylpyrazine derivatives
CN105949135A (zh) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 一种赛乐西帕的合成方法
CA3029960A1 (en) * 2016-07-05 2018-01-11 Maithri Drugs Private Limited Novel process for the preparation of 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-n-(methylsulfonyl)acetamide and novel polymorphs thereof
WO2018015974A1 (en) * 2016-07-20 2018-01-25 Mylan Laboratories Limited Polymorphic forms and amorphous solid dispersion of selexipag
WO2018022704A1 (en) * 2016-07-26 2018-02-01 Teva Pharmaceuticals International Gmbh Crystalline form vi of selexipag
WO2018078383A1 (en) 2016-10-27 2018-05-03 Cipla Limited Pharmaceutical composition comprising amorphous selexipag
CN108069914A (zh) * 2016-11-17 2018-05-25 江苏艾立康药业股份有限公司 一种西里帕格晶型的制备方法
EP3554507A1 (en) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
EP3335699A1 (en) 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
JP2020528900A (ja) 2017-07-27 2020-10-01 アラーガン、インコーポレイテッドAllergan,Incorporated 体脂肪低減のためのプロスタサイクリン受容体アゴニスト
MX2020007315A (es) 2017-09-28 2020-08-20 Nippon Shinyaku Co Ltd Cristal.
AR113882A1 (es) * 2017-11-16 2020-06-24 Nippon Shinyaku Co Ltd Preparación de liberación controlada
US10407396B2 (en) 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
CN111699175B (zh) 2018-02-07 2022-03-29 南京明德新药研发有限公司 前列环素受体受体激动剂
AR114399A1 (es) * 2018-02-21 2020-09-02 Nippon Shinyaku Co Ltd Composición granular, método de producción para composición granular y método de mejora de la propiedad de disolución para composición granular
CN109125325B (zh) * 2018-09-25 2021-05-25 中国人民解放军总医院 前列环素受体激动剂的医药用途
WO2020157730A1 (en) 2019-02-03 2020-08-06 Patel Jayendrakumar Dasharathlal A controlled release pharmaceutical composition of selexipag or it's active metabolite
EP3705115B1 (en) 2019-03-07 2021-06-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition containing selexipag
EP3965767A1 (en) 2019-05-06 2022-03-16 Actelion Pharmaceuticals Ltd Methods for treating sarcoidosis-associated pulmonary hypertension
US12419887B2 (en) 2019-05-21 2025-09-23 Actelion Pharmaceuticals Ltd. Transitioning patients treated for pulmonary arterial hypertension to selexipag
EP3982967A1 (en) 2019-06-11 2022-04-20 Actelion Pharmaceuticals Ltd. Methods for treating pulmonary arterial hypertension
WO2021023271A1 (zh) * 2019-08-06 2021-02-11 南京明德新药研发有限公司 作为前列环素受体激动剂的化合物的晶型及其制备方法
JP7646646B2 (ja) 2019-10-23 2025-03-17 日本新薬株式会社 セレキシパグを含む医薬組成物
IL293271A (en) 2019-11-29 2022-07-01 Actelion Pharmaceuticals Ltd Methods for treating pulmonary artery hypertension
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス,インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症(PH-HF-pEF)を治療するためのレボシメンダン
JP2023512273A (ja) 2020-01-31 2023-03-24 アクテリオン ファーマシューティカルズ リミテッド 制御放出セレキシパグ組成物
US20230073428A1 (en) 2020-02-03 2023-03-09 Actelion Pharmaceuticals Ltd Methods of treating and assessing pulmonary arterial hypertension with selexipag
CN112500358B (zh) * 2020-11-18 2022-03-15 江苏豪森药业集团有限公司 赛乐西帕晶型及其制备方法
WO2022106621A1 (en) 2020-11-20 2022-05-27 Actelion Pharmaceuticals Ltd Selexipag for use via intracolonic administration
CN116744903A (zh) * 2021-01-29 2023-09-12 埃科特莱茵药品有限公司 包含二苯基吡嗪衍生物的药物组合物
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
EP4456897A4 (en) 2021-12-31 2025-12-10 Tenax Therapeutics Inc ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative
WO2024133620A1 (en) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd In vitro dissolution test
WO2024142718A1 (ja) * 2022-12-27 2024-07-04 株式会社トクヤマ セレキシパグのi型結晶の製造方法
EP4616904A3 (en) * 2022-12-28 2025-10-29 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A formulation comprising selexipag
EP4393476A1 (en) * 2022-12-28 2024-07-03 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet formulation comprising selexipag
EP4393475A1 (en) 2022-12-28 2024-07-03 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations comprising selexipag
WO2024194449A1 (en) 2023-03-23 2024-09-26 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising a diphenylpyrazine derivative
WO2025196095A1 (en) 2024-03-20 2025-09-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition for treating pulmonary hypertension

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002088084A (ja) 2000-08-03 2002-03-27 Pfizer Prod Inc ジアザビシクロオクタン誘導体およびそれらの治療的使用
JP2009157396A (ja) 2003-07-29 2009-07-16 Canon Inc 非磁性トナー
WO2009107736A1 (ja) 2008-02-28 2009-09-03 日本新薬株式会社 線維化抑制剤
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
WO2009157398A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 炎症性腸疾患治療剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092760A1 (en) 2001-03-12 2003-05-15 Toray Industries, Inc. Therapeutic agent for renal failure
EP1106176B1 (en) 1999-05-10 2008-06-18 Toray Industries, Inc. Remedies for renal failure
WO2002085412A1 (en) * 2001-04-18 2002-10-31 Fujisawa Pharmaceutical Co., Ltd. Tissue fibrosis inhibitors
TWI316055B (cg-RX-API-DMAC10.html) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
CN1787824A (zh) 2003-06-25 2006-06-14 有限会社循环器研究所 性交功能改善用外用制剂
HRP20151443T1 (hr) 2008-06-23 2016-01-29 Nippon Shinyaku Co., Ltd. Terapijsko sredstvo protiv stenoze kralježniäśnog kanala
US8575175B2 (en) 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
DK2343292T3 (da) 2008-09-10 2014-11-03 Asahi Glass Co Ltd Nyt prostaglandin 12-derivat

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002088084A (ja) 2000-08-03 2002-03-27 Pfizer Prod Inc ジアザビシクロオクタン誘導体およびそれらの治療的使用
JP2009157396A (ja) 2003-07-29 2009-07-16 Canon Inc 非磁性トナー
WO2009107736A1 (ja) 2008-02-28 2009-09-03 日本新薬株式会社 線維化抑制剤
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
WO2009157398A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 炎症性腸疾患治療剤

Also Published As

Publication number Publication date
CA2764475C (en) 2017-04-25
US8791122B2 (en) 2014-07-29
KR20120109457A (ko) 2012-10-08
HK1244788A1 (en) 2018-08-17
PL3275871T3 (pl) 2020-07-27
RU2012102678A (ru) 2013-08-10
US20150266830A1 (en) 2015-09-24
CA2764475A1 (en) 2010-12-29
DK3275871T3 (da) 2020-04-06
PH12015502825B1 (en) 2017-12-11
KR20240090716A (ko) 2024-06-21
RU2556206C3 (ru) 2021-06-15
PH12015502825A1 (en) 2017-12-11
IL216928A0 (en) 2012-02-29
HRP20180171T1 (hr) 2018-03-09
CO6430432A2 (es) 2012-04-30
EP2447254A1 (en) 2012-05-02
IL216928A (en) 2016-10-31
HUE048467T2 (hu) 2020-07-28
KR102829415B1 (ko) 2025-07-03
AU2010263569A1 (en) 2012-02-02
HRP20200539T1 (hr) 2020-07-10
SI2447254T1 (en) 2018-03-30
DK2447254T3 (en) 2018-01-15
CN102459198A (zh) 2012-05-16
NZ597352A (en) 2013-01-25
KR102669213B1 (ko) 2024-05-28
BRPI1015936A2 (pt) 2016-08-16
PT3275871T (pt) 2020-04-21
EP2447254A4 (en) 2012-12-19
IL243293A0 (en) 2016-02-29
US20120101276A1 (en) 2012-04-26
SG10201403313WA (en) 2014-10-30
PT2447254T (pt) 2018-01-04
MA33637B1 (fr) 2012-10-01
KR20240090717A (ko) 2024-06-21
CN104326991A (zh) 2015-02-04
MX346318B (es) 2017-03-15
AR077242A1 (es) 2011-08-10
EP3275871A1 (en) 2018-01-31
JPWO2010150865A1 (ja) 2012-12-10
KR102705198B1 (ko) 2024-09-11
HUE036721T2 (hu) 2018-07-30
BRPI1015936B1 (pt) 2021-07-13
CY1119788T1 (el) 2018-06-27
PH12015502824A1 (en) 2017-05-29
AU2010263569B2 (en) 2016-08-18
CY1122893T1 (el) 2021-05-05
SMT201800077T1 (it) 2018-03-08
LTC2447254I2 (lt) 2022-04-25
TWI531565B (zh) 2016-05-01
LT3275871T (lt) 2020-05-11
NO2018015I1 (no) 2018-04-23
HUS1800015I1 (hu) 2018-05-28
SI3275871T1 (sl) 2020-06-30
EP3689855A1 (en) 2020-08-05
IL243287A0 (en) 2016-02-29
SG176915A1 (en) 2012-01-30
RU2556206C2 (ru) 2015-07-10
BR122021005510B1 (pt) 2022-01-11
ES2660007T3 (es) 2018-03-20
ZA201109099B (en) 2012-08-29
KR20250107951A (ko) 2025-07-14
US9440931B2 (en) 2016-09-13
ES2797124T3 (es) 2020-12-01
WO2010150865A1 (ja) 2010-12-29
MX2011013471A (es) 2012-01-30
TW201111352A (en) 2011-04-01
CL2011003264A1 (es) 2012-07-06
PL2447254T3 (pl) 2018-05-30
CY2018011I2 (el) 2018-09-05
MY186531A (en) 2021-07-25
IL243287B (en) 2021-04-29
US9340516B2 (en) 2016-05-17
US20140155414A1 (en) 2014-06-05
US9284280B2 (en) 2016-03-15
CY2018011I1 (el) 2018-09-05
SMT202000177T1 (it) 2020-05-08
LT2447254T (lt) 2018-01-10
CN102459198B (zh) 2014-09-24
EP2447254B1 (en) 2017-12-06
EP3275871B1 (en) 2020-01-15
NO2447254T3 (cg-RX-API-DMAC10.html) 2018-05-05
US20140148469A1 (en) 2014-05-29
LTPA2018008I1 (lt) 2018-05-10
US8791122C1 (cg-RX-API-DMAC10.html) 2014-07-29

Similar Documents

Publication Publication Date Title
KR102669213B1 (ko) 결정
TW202114998A (zh) 鹽
JP2022173401A (ja) 結晶
TWI496773B (zh) N-[2-[[(2,3-二氟苯基)甲基]硫基]-6-{[(1r,2s)-2,3-二羥基-1-甲基丙基]氧基}-4-嘧啶基]-1-三亞甲亞胺磺醯胺之新穎結晶型
HK1244788B (en) Crystals
HK1165421A (en) Crystals
HK1165421B (en) Crystals

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170224

Application number text: 1020127000526

Filing date: 20120106

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170322

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170501

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170821

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170501

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20170920

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20170821

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190328

Appeal identifier: 2017101004469

Request date: 20170920

J301 Trial decision

Free format text: TRIAL NUMBER: 2017101004469; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20170920

Effective date: 20190328

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20190328

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20170920

Decision date: 20190328

Appeal identifier: 2017101004469

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2019201004420; APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20190328

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2019201004420

Request date: 20190607